vTv Therapeutics (VTVT) Short-Term Debt issuances (2017)

vTv Therapeutics (VTVT) reported Short-Term Debt issuances of $7.5 million for Q1 2017.

vTv Therapeutics (VTVT) Short-Term Debt issuances (2017) Analysis & Trends

vTv Therapeutics (VTVT) has 1 years of Short-Term Debt issuances data on file, last reported at $7.5 million in Q1 2017.

For the quarter ending Q1 2017, Short-Term Debt issuances changed N/A year-over-year to $7.5 million; the trailing twelve-month figure through Dec 2017 stood at $7.5 million (changed N/A YoY), and the FY2017 full-year result was $7.5 million, down 40.0% from the prior year.
Short-Term Debt issuances was little changed at $7.5 million in Q1 2017.
In the past five years, Short-Term Debt issuances ranged from a high of $7.5 million in Q1 2017 to a low of $7.5 million in Q1 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Short-Term Debt issuances (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	102,000.00
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	58.20 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	-
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	vTv Therapeutics	19.21 Mn	19.21 Mn	-	-

Download Data

Date	Value
Mar 31, 2017	7.50 Mn
Mar 31, 2017	7.50 Mn